Balanced news tone
News Sentiment
RKDA sentiment intelligence
Arcadia Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
50
Balanced news tone
40 relevant articles
Price is moving more forcefully than the current news tone suggests.
84/100 classification confidence.
directly relevant articles
high-authority source matches
-6.6% over one week, -33.5% over four weeks, trend inactive, and below fair value.
Arcadia Biosciences (RKDA) registers 11.9M resale shares from 2026 private placement
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
84/100 classification
One-week reaction
-6.6%
Price reacting lower
Trend fit
Trend inactive
-33.5% over four weeks
Fair value
-78.4%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
9
Neutral
25
Negative
6
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Stock Titan
Direct company coverage
Arcadia Biosciences (RKDA) registers 11.9M resale shares from 2026 private placement
Arcadia Biosciences is registering 11.9 million shares of common stock for resale by existing stockholders, which are issuable upon the exercise of pre-funded warrants, preferred investment options, and placement agent options from a private placement completed in June 2026. The
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 10:31
- Source
- Stock Titan
Stock Titan
Direct company coverage
[EFFECT] Arcadia Biosciences, Inc. SEC Filing
This article reports on an SEC filing by Arcadia Biosciences, Inc. (RKDA), detailing a Notice of Effectiveness for an S-3 form with an effectiveness date of July 8, 2026, at 5:00 P.M. The filing indicates a neutral impact and sentiment. The article also provides an overview of RK
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 10:31
- Source
- Stock Titan
TradingView
Direct company coverage
Price to sales forward of Arcadia Biosciences, Inc. – NASDAQ:RKDA
The article focuses on the "Price to sales forward" metric for Arcadia Biosciences, Inc. (NASDAQ: RKDA). It is presented as a financial data point available on TradingView, within the company's financial overview. The content primarily highlights the financial metric without prov
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jul 2026 18:40
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Arcadia Biosciences, Inc. – NASDAQ:RKDA
This article displays the "Price to earnings forward" financial metric for Arcadia Biosciences, Inc. (NASDAQ: RKDA). It indicates that there are currently no trades and the market is closed for this stock. The content appears to be a stub or a placeholder from a financial data pl
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 04 Jul 2026 09:10
- Source
- TradingView
Stock Titan
Direct company coverage
RKDA SEC Filings - Arcadia Bioscien 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Arcadia Biosciences (RKDA) SEC filings, including 10-K, 10-Q, and 8-K reports. It details recent material events such as the CFO's resignation and the CEO taking an interim finance role, as well as financial disclosures from Q2 2025
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jul 2026 06:09
- Source
- Stock Titan
GuruFocus
Direct company coverage
Arcadia Biosciences Inc (FRA:17D) - Valuation Measures & Financial Statistics
This article provides key valuation measures and financial statistics for Arcadia Biosciences Inc (FRA:17D) as of July 3. The company is currently operating at a loss with a P/B ratio of 0.52 and a market capitalization of €1.40M. It also highlights four severe warning signs dete
- Tone
- Negative 26/100
- Event
- Market update
- Published
- 04 Jul 2026 05:10
- Source
- GuruFocus
Ad-hoc-news.de
Direct company coverage
Arcadia Biosciences focuses on plant-based innovation for future growth
Arcadia Biosciences is a biotechnology company focused on plant-based science for health, nutrition, and agriculture. The company aims to create long-term value through innovation in crops and plant-derived compounds, emphasizing intellectual property, strategic product developme
- Tone
- Positive 64/100
- Event
- Market update
- Published
- 03 Jul 2026 14:09
- Source
- Ad-hoc-news.de
TradingView
Direct company coverage
Arcadia Biosciences awards discretionary bonus to Thomas J. Schaefer
Arcadia Biosciences approved a discretionary cash bonus for Thomas J. Schaefer, its CEO and Interim CFO, for his services in 2025. The bonus amount is $169,000, and it was approved by the Board and Compensation Committee. This announcement also noted the resignation of former CFO
- Tone
- Positive 59/100
- Event
- Balance sheet
- Published
- 02 Jul 2026 20:40
- Source
- TradingView
Stock Titan
Direct company coverage
Arcadia Biosciences (NASDAQ: RKDA) grants CEO bonus and sets 2026 vote deadlines
Arcadia Biosciences (NASDAQ: RKDA) has updated its executive compensation, awarding CEO Thomas J. Schaefer a discretionary cash bonus of $169,000 for 2025, bringing his total compensation to $473,058. The company also announced that its 2026 annual meeting of stockholders will be
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 02 Jul 2026 20:40
- Source
- Stock Titan
Moomoo
Direct company coverage
Arcadia Biosciences | 424B3: Prospectus
This document is a 424B3 prospectus filing for Arcadia Biosciences. A prospectus is a formal legal document that is required by and filed with the SEC, providing details about an investment offering for sale to the public.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 04:09
- Source
- Moomoo
Investing.com
Direct company coverage
Form S-3 Arcadia Biosciences Inc For: 26 June
This article announces the filing of Form S-3 by Arcadia Biosciences Inc. for June 26. It includes a standard Investing.com disclaimer about the high risks associated with trading financial instruments and cryptocurrencies, emphasizing that the data provided may not be real-time
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 04:09
- Source
- Investing.com
TradingView
Direct company coverage
Enterprise value to revenue forward of Arcadia Biosciences, Inc. – NASDAQ:RKDA
This article displays the "Enterprise value to revenue forward" metric for Arcadia Biosciences, Inc. (NASDAQ: RKDA) on TradingView. It indicates that the market was closed at the time of viewing, with no trades activity. The content specifically highlights the financial metric fo
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 02:40
- Source
- TradingView
Stock Titan
Direct company coverage
Arcadia Biosciences (RKDA) registers 11.9M shares for resale; options convertible
Arcadia Biosciences (RKDA) has filed an S-3 registration statement for the resale of up to 11.9 million shares of common stock, which are issuable upon the exercise of pre-funded warrants, preferred investment options, and placement agent options. The company will not receive pro
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 20:40
- Source
- Stock Titan
TradingView
Direct company coverage
Arcadia Biosciences, Inc. Actuals & Estimates (NASDAQ:RKDA)
This article provides an overview of Arcadia Biosciences, Inc. (NASDAQ: RKDA) stock performance, financial actuals, and estimates. It covers current stock price, market capitalization, volatility, past earnings, and upcoming earnings reports, along with other financial metrics an
- Tone
- Negative 31/100
- Event
- Earnings
- Published
- 26 Jun 2026 15:09
- Source
- TradingView
TradingView
Direct company coverage
Arcadia Biosciences, Inc. Actuals & Estimates (GETTEX:17D)
This article provides an overview of Arcadia Biosciences, Inc. (GETTEX:17D), including its current stock price, market capitalization, and historical performance. It details financial actuals and estimates, such as earnings and revenue, and notes upcoming earnings report dates. T
- Tone
- Negative 33/100
- Event
- Earnings
- Published
- 25 Jun 2026 21:39
- Source
- TradingView
TradingKey
Direct company coverage
Arcadia Biosciences Inc (RKDA) Financial Health: Profitability & Balance Sheet Analysis
Arcadia Biosciences Inc (RKDA) has a current financial score of 6.21, ranking 75 out of 95 in the Food & Tobacco industry, indicating a robust financial status despite low operating efficiency. The company's latest quarterly revenue was $1.10M, an 8.33% year-over-year decrease, a
- Tone
- Negative 29/100
- Event
- Earnings
- Published
- 23 Jun 2026 09:39
- Source
- TradingKey
TradingKey
Direct company coverage
Arcadia Biosciences Inc (RKDA) Valuation: PE, PB & Fair Value Analysis
Arcadia Biosciences Inc (RKDA) currently holds a valuation score of 8.65, placing it 37th out of 95 companies in the Food & Tobacco industry as of June 18, 2026. The company's P/E ratio is -0.14, which is significantly below its recent high and above its recent low. Key valuation
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Jun 2026 00:38
- Source
- TradingKey
TradingKey
Direct company coverage
Arcadia Biosciences Inc (RKDA) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for Arcadia Biosciences Inc (RKDA), detailing analyst ratings, price targets, and future revenue and EPS expectations. It notes that no earnings forecast score is currently available, but highlights a consensus "Buy" rating from one analy
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 19 Jun 2026 13:09
- Source
- TradingKey
TradingKey
Direct company coverage
Arcadia Biosciences Inc (RKDA) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Arcadia Biosciences Inc (RKDA), highlighting its current price momentum score of 6.42 and identifying resistance at 1.56 and support at 0.38. Technical indicators, including MACD, RSI, and CCI, largely suggest a "Sell" signal, while a
- Tone
- Negative 30/100
- Event
- Market update
- Published
- 19 Jun 2026 11:09
- Source
- TradingKey
TradingKey
Direct company coverage
Arcadia Biosciences Inc (RKDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Arcadia Biosciences Inc (RKDA), highlighting regional revenue contribution with specific figures for the United States at $4.86 million. It notes that relevant data for business segments, India, Canada, and Argentina have not yet been
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 17 Jun 2026 01:39
- Source
- TradingKey
GlobeNewswire
Direct company coverage
Arcadia Biosciences (RKDA) Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Arcadia Biosciences (RKDA) has announced a private placement totaling $4 million through the sale of common stock and preferred investment options. The offering, priced at-the-market under Nasdaq rules, is expected to close around June 12, 2026, with proceeds intended for working
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 04:39
- Source
- GlobeNewswire
TradingView
Direct company coverage
Arcadia Biosciences Raises ~$4 Million in Private Placement of Pre-Funded Warrants and Options
Arcadia Biosciences announced a private placement raising approximately $4 million from an institutional accredited investor through the issuance of pre-funded warrants and Series A-1 and A-2 preferred investment options. The company also signed a registration rights agreement to
- Tone
- Positive 65/100
- Event
- Market update
- Published
- 15 Jun 2026 15:10
- Source
- TradingView
Stock Titan
Direct company coverage
Arcadia Biosciences (RKDA) completes $4M private placement with warrants and options
Arcadia Biosciences (RKDA) has completed a $4 million private placement, issuing pre-funded warrants and Series A-1 and A-2 preferred investment options to an institutional accredited investor. The transaction, priced at $1.03 per unit under
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 15:10
- Source
- Stock Titan
The Manila Times
Direct company coverage
Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Arcadia Biosciences, Inc. (Nasdaq: RKDA) has announced the closing of a $4 million private placement. The placement involved the sale of common stock or pre-funded warrants, along with Series A-1 and A-2 preferred investment options, priced at $1.03 per share under Nasdaq rules,
- Tone
- Positive 67/100
- Event
- Market update
- Published
- 15 Jun 2026 07:09
- Source
- The Manila Times
Moomoo
Direct company coverage
Arcadia Biosciences, Inc. Announces Private Placement of Common Stock and Preferred Investment Options to Raise Approximately $4 Million
Arcadia Biosciences, Inc. (NASDAQ: RKDA) announced a private placement aiming to raise around $4 million. The offering includes common stock and preferred stock options, with the proceeds intended for working capital and general corporate purposes. This strategic move is expected
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 15 Jun 2026 07:09
- Source
- Moomoo
Moomoo
Direct company coverage
Press Release: Arcadia Biosciences (RKDA) Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Arcadia Biosciences (RKDA) announced a private placement of 4 million shares of its common stock to institutional investors, priced at $1.00 per share, resulting in gross proceeds of $4 million. The offering is expected to close around December 13, 2024, and the company plans to
- Tone
- Positive 59/100
- Event
- Market update
- Published
- 14 Jun 2026 09:41
- Source
- Moomoo
Investing.com Nigeria
Direct company coverage
Arcadia Biosciences closes $4 million private placement By Investing.com
Arcadia Biosciences (NASDAQ:RKDA) has completed a private placement, raising approximately $4 million in gross proceeds. The company sold nearly 3.9 million shares of common stock or pre-funded warrants at $1.03 per share, which is significant given its current market capitalizat
- Tone
- Positive 60/100
- Event
- Market update
- Published
- 13 Jun 2026 10:39
- Source
- Investing.com Nigeria
Quiver Quantitative
Direct company coverage
Arcadia Biosciences, Inc. Closes $4 Million Private Placement of Common Stock and Preferred Investment Options
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jun 2026 07:00
- Source
- Quiver Quantitative
Stock Titan
Direct company coverage
Arcadia Biosciences raises $4M in at-the-market stock deal
Arcadia Biosciences (Nasdaq: RKDA) has closed a $4 million private placement, selling 3,883,496 common shares (or pre-funded warrants) and associated Series A-1 and A-2 preferred investment options at $1.03 per share. The net proceeds will be used for working capital and general
- Tone
- Negative 38/100
- Event
- Deals and strategy
- Published
- 13 Jun 2026 02:10
- Source
- Stock Titan
MT Newswires
Direct company coverage
Arcadia Biosciences Raises $4 Million in Private Placement
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 12 Jun 2026 07:26
- Source
- MT Newswires